ClearPoint Neuro, Inc. financial data

Symbol
CLPT on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
120 S. Sierra Avenue, Suite 100, Solana Beach, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
MRI INTERVENTIONS, INC. (to 2/11/2020), SURGIVISION INC (to 10/22/2010), SURGI VISION INC (to 5/2/2007)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 471 % -44.7%
Quick Ratio 99.1 % -28.9%
Debt-to-equity 75.1 % +59.6%
Return On Equity -76.9 % -61.8%
Return On Assets -43.9 % -35.9%
Operating Margin -80.1 % +7.64%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27M shares +9.74%
Common Stock, Shares, Outstanding 27.4M shares +11.5%
Entity Public Float 155M USD -43%
Common Stock, Value, Issued 274K USD +11.4%
Weighted Average Number of Shares Outstanding, Basic 25.5M shares +3.54%
Weighted Average Number of Shares Outstanding, Diluted 25.5M shares +3.54%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 26.2M USD +24.9%
Revenue from Contract with Customer, Excluding Assessed Tax 26.2M USD +24.9%
Cost of Revenue 11.2M USD +50.6%
Research and Development Expense 11.3M USD +2.68%
Selling and Marketing Expense 13M USD +26.1%
Operating Income (Loss) -21M USD -15.3%
Income Tax Expense (Benefit) 8K USD
Net Income (Loss) Attributable to Parent -20.6M USD -14.1%
Earnings Per Share, Basic -0.83 USD/shares -12.2%
Earnings Per Share, Diluted -0.83 USD/shares -12.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.4M USD +62.2%
Accounts Receivable, after Allowance for Credit Loss, Current 2.51M USD -6.24%
Inventory, Net 7.96M USD -18.8%
Assets, Current 47.6M USD +3.45%
Property, Plant and Equipment, Net 1.35M USD +41.9%
Operating Lease, Right-of-Use Asset 3.45M USD +95.6%
Other Assets, Noncurrent 149K USD +13.7%
Assets 53.6M USD +6.75%
Accounts Payable, Current 844K USD -37.6%
Employee-related Liabilities, Current 1.63M USD +12.4%
Liabilities, Current 15.2M USD +150%
Operating Lease, Liability, Noncurrent 3.44M USD +148%
Liabilities 19.1M USD +7.85%
Retained Earnings (Accumulated Deficit) -177M USD -13.2%
Stockholders' Equity Attributable to Parent 34.6M USD +6.15%
Liabilities and Equity 53.6M USD +6.75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.84M USD +32.4%
Net Cash Provided by (Used in) Financing Activities 16.1M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 90M shares -55%
Common Stock, Shares, Issued 27.4M shares +11.5%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.4M USD +62.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 185K USD +3.35%
Deferred Tax Assets, Valuation Allowance 35.8M USD +18.8%
Deferred Tax Assets, Gross 35.9M USD +18.7%
Operating Lease, Liability 3.99M USD +90.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 6.35M USD +194%
Property, Plant and Equipment, Gross 2.33M USD -9.36%
Operating Lease, Liability, Current 497K USD -13%
Lessee, Operating Lease, Liability, to be Paid, Year Two 954K USD +63.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 869K USD +46.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +34.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.36M USD +3316%
Lessee, Operating Lease, Liability, to be Paid, Year Three 985K USD +103%
Deferred Tax Assets, Operating Loss Carryforwards 30.1M USD +13.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 502K USD +0.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 243K USD +88.4%
Deferred Tax Assets, Net of Valuation Allowance 38K USD -2.56%
Share-based Payment Arrangement, Expense 6.28M USD +38.4%
Interest Expense 81K USD -91.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%